Is XBI a good investment?
State Street SPDR S&P Biotech ETF (XBI) is a healthcare and biotech ETF. As of September 11, 2026, ETF Copilot scores XBI 2.7 out of 10 — highest on Return (4.7), lowest on Risk (1.4). It trades at 23.3 times earnings, against its own median of 17.7. Its ten largest holdings are 16% of the fund.
Updated September 11, 2026
How is XBI rated? ETF Copilot scores State Street SPDR S&P Biotech ETF (XBI) 2.7 out of 10
As of September 11, 2026, ETF Copilot scores State Street SPDR S&P Biotech ETF (XBI) 2.7 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 2.7 / 10
- Growth: 1.6 / 10
- Risk: 1.4 / 10
- Quality: 2.5 / 10
- Return: 4.7 / 10
What is XBI's expense ratio? 0.35% a year
As of September 11, 2026, XBI charges 0.35% a year, yields 0.15% and holds $11.3B in assets across 145 positions.
| Measure | XBI |
|---|---|
| Expense ratio | 0.35% |
| Dividend yield | 0.15% |
| Assets under management | $11.3B |
| Holdings | 145 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
What stands out in XBI's data
U.S. biotech industry stocks, tracked through a core index.
Earns less on its operations than most biotech peers — a sign the companies it holds are still spending heavily on research.
EBITDA margin of 10.4% trails the 21.2% category median, well below the fund's own 13.0% historical average. Dividend yield sits at 0.1%.
A focused sector bet on biotech, built for portfolios that want direct exposure to drug development.
Why did XBI move this week? It fell 5.0% in the week to September 11, 2026 — Dyne Therapeutics and Sellas Life Sciences drove it
XBI fell 5.0% in the week to September 11, 2026. The holdings that moved it most were Dyne Therapeutics (−27.0%), Sellas Life Sciences (−15.7%) and Amgen (−15.0%); Roivant Sciences (+18.6%) pushed the other way.
Is XBI expensive right now? It trades at 23.3 times earnings, against its own median of 17.7
As of September 11, 2026, XBI is more expensive than 79% of its own 114 monthly readings since 2017 — 90 of those months were cheaper than today.
Trailing twelve-month, computed by ETF Copilot from the fund's holdings rather than quoted from a data provider, and rebuilt nightly.
What's inside XBI?
What's inside XBI: Size (Large 14%, Mid 41%, Small 45%); Geography (International 6%, US 94%).
What are XBI's top holdings? The ten largest are 16% of the fund
Moderna, Twist Bioscience, Halozyme Therapeutics, Natera, Kymera Therapeutics, Travere Therapeutics, Roivant Sciences, Oruka Therapeutics, Revolution Medicines and Praxis Precision Medicines are XBI's largest holdings, in that order.
Less concentrated than 98% of Healthcare & Biotech ETFs.
Half of XBI's weight sits in its 40 largest positions, and once those weights are taken into account it behaves like 100 equally weighted holdings.
Cite this
ETF Copilot, “State Street SPDR S&P Biotech ETF (XBI) scores and holdings analysis”, as of September 11, 2026.
https://etf-copilot.com/etf/xbi
Register free to unlock XBI's price and what each holding weighs on ETF Copilot.
Register free →